Adaptive Biotechnologies Corporation (MUN:1HM)
13.18
0.00 (0.00%)
Last updated: Dec 16, 2025, 8:00 AM CET
Adaptive Biotechnologies Revenue
Adaptive Biotechnologies had revenue of $93.97M USD in the quarter ending September 30, 2025, with 102.38% growth. This brings the company's revenue in the last twelve months to $252.75M, up 42.57% year-over-year. In the year 2024, Adaptive Biotechnologies had annual revenue of $178.96M with 5.10% growth.
Revenue (ttm)
$252.75M
Revenue Growth
+42.57%
P/S Ratio
9.45
Revenue / Employee
$408.33K
Employees
619
Market Cap
2.04B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 178.96M | 8.68M | 5.10% |
| Dec 31, 2023 | 170.28M | -15.03M | -8.11% |
| Dec 31, 2022 | 185.31M | 30.96M | 20.06% |
| Dec 31, 2021 | 154.34M | 55.96M | 56.88% |
| Dec 31, 2020 | 98.38M | 13.31M | 15.65% |
| Dec 31, 2019 | 85.07M | 29.41M | 52.83% |
| Dec 31, 2018 | 55.66M | 17.22M | 44.77% |
| Dec 31, 2017 | 38.45M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mercedes-Benz Group AG | 136.97B |
| Bayerische Motoren Werke Aktiengesellschaft | 136.42B |
| Deutsche Telekom AG | 121.02B |
| Allianz SE | 105.02B |
| Deutsche Post AG | 84.05B |
| Siemens Aktiengesellschaft | 78.91B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Siemens Energy AG | 39.08B |
Adaptive Biotechnologies News
- 20 hours ago - Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million - Reuters
- 20 hours ago - Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer - GlobeNewsWire
- 3 days ago - Insider Sell: Robert Hershberg Sells 22,968 Shares of Adaptive Biotechnologies Corp (ADPT) - GuruFocus
- 6 days ago - Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease - GlobeNewsWire
- 8 days ago - Adaptive Biotechnologies (ADPT) Showcases clonoSEQ Test Advances at ASH Meeting - GuruFocus
- 9 days ago - Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ Data Driving Treatment Interventions at 2025 ASH Annual Meeting - Wallstreet:Online
- 9 days ago - Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting - GlobeNewsWire
- 10 days ago - Insider Sell: Harlan Robins Sells 37,212 Shares of Adaptive Biotechnologies Corp (ADPT) - GuruFocus